CoChat

Albendazole: a review of anthelmintic efficacy and safety in humans

HORTON, J. · 2000 · Parasitology

The DOI matches its Crossref record.

Abstract

This comprehensive review briefly describes the history and pharmacology of albendazole as an anthelminthic drug and presents detailed summaries of the efficacy and safety of albendazole's use as an anthelminthic in humans. Cure rates and % egg reduction rates are presented from studies published through March 1998 both for the recommended single dose of 400mg for hookworm (separately for Necator americanus and Ancylostoma duodenale when possible), Ascaris lumbricoides, Trichuris trichiura, and Enterobius vermicularis and, in separate tables, for doses other than a single dose of 400mg. Overall cure rates are also presented separately for studies involving only children 2–15 years. Similar tables are also provided for the recommended dose of 400mg per day for 3 days in Strongyloides stercoralis, Taenia spp. and Hymenolepis nana infections and separately for other dose regimens. The remarkable safety record involving more than several hundred million patient exposures over a 20 year period is also documented, both with data on adverse experiences occurring in clinical trials and with those in the published literature and/or spontaneously reported to the company. The incidence of side effects reported in the published literature is very low, with only gastrointestinal side effects occurring with an overall frequency of just >1%. Albendazole's unique broad-spectrum activity is exemplified in the overall cure rates calculated from studies employing the recommended doses for hookworm (78% in 68 studies: 92% for A. duodenale in 23 studies and 75% for N. americanus in 30 studies), A. lumbricoides (95% in 64 studies), T. trichiura (48% in 57 studies), E. vermicularis (98% in 27 studies), S. stercoralis (62% in 19 studies), H. nana (68% in 11 studies), and Taenia spp. (85% in 7 studies). The facts that albendazole is safe and easy to administer, both in treatment of individuals and in treatment of whole communities where it has been given by paramedical and nonmedical personnel, have enabled its use to improve general community health, including the improved nutrition and development of children.

Overview

Integrity signals

Registry

Crossref · 10.1017/s0031182000007290

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

5 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Still being checked.

Cited by

See all 386

Metadata

Authors
HORTON, J.
Corresponding author
HORTON, J.
Venue
Parasitology
Published
2000-10
Volume
121
Issue
S1
Pages
S113-S132
ISSN
  • 0031-1820 (ISSN-L)
  • 1469-8161
OpenAlex
W2088719505
Cited by
386
References
0
Citations by year
2026: 22 · 2025: 17 · 2024: 13 · 2023: 25 · 2022: 28 · 2021: 25 · 2020: 28 · 2019: 17 · 2018: 13 · 2017: 14 · 2016: 17 · 2015: 22 · 2014: 12 · 2013: 15 · 2012: 10
FWCI
4.08
Type
journal article
Language
en
Open access
closed
Locations
  • Parasitology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Parasitology › Parasites and Host Interactions
  • Health Sciences › Medicine › Infectious Diseases › Parasitic Diseases Research and Treatment
  • Life Sciences › Immunology and Microbiology › Parasitology › Helminth infection and control
Keywords
albendazole, anthelmintic efficacy, drug safety, hookworm infection, Necator americanus, Ancylostoma duodenale, Ascaris lumbricoides, Trichuris trichiura, Enterobius vermicularis, Strongyloides stercoralis, Taenia, Hymenolepis nana, cure rate, egg reduction rate, dosing regimen, pediatric parasitic infection, gastrointestinal adverse effects
MeSH terms
Adolescent, Adult, Anthelmintics, Child, Clinical Trials as Topic, Female, Humans, Male, Nematode Infections, Albendazole

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Albendazole: a review of anthelmintic efficacy and safety in humans. https://app.cochat.ai/papers/10.1017/s0031182000007290
The paper
HORTON, J. (2000). Albendazole: a review of anthelmintic efficacy and safety in humans. Parasitology. https://doi.org/10.1017/s0031182000007290

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.